SYNTHESIS OF SUBSTITUTED 1,2,3,4-TETRAHYDROBENZO[*b*][1,6]NAPHTHYRIDINES

Ewa Wolinska,^a Ekaterina Paliakov and Lucjan Strekowski* Department of Chemistry, Georgia State University, Atlanta, Georgia 30302-4098, USA e-mail : lucjan@gsu.edu

Abstract: Synthesis of the substituted compounds 9-14 (2-Me or 2-Et; 6-H, 6-OMe or 6-OH; 9-NHR) is reported.

A number of basic quinolines induce remissions of rheumatoid arthritis and systemic lupus erythematosus, which are autoimmune diseases.^{1,2} It has also been suggested that such compounds, by temporarily suppressing the immune system, may be useful in the prevention of graft-versus-host disease in bone marrow transplant patients.³ Our recent research *in vitro* has shown that the basicity of the N1 atom of the quinoline parallels the activity of the immunosuppressive agents and the most active compounds contain additional amino (basic) centers and polar substituents, such as a hydroxy group. Importantly, inhibition of the immunostimulation is observed for relatively small quinolines only.⁴

This report pertains to the synthesis of 1,2,3,4-tetrahydrobenzo[b][1,6]naphthyridines 9-14 as potential immunosuppressive agents. As can be seen, the molecules 9-14 are substituted quinolin-4-amines, the N1 atom of which is basic (pK_a > 7) due to conjugation of the N⁴ atom with the quinoline.⁴ Additional basic centers are parts of the side chain and the fused aliphatic ring. Derivatives 12-14 contain a polar methoxy or hydroxy group.



^a On leave of absence from the University of Podlasie, Poland

The intermediate 9-chloro-1,2,3,4-tetrahydrobenzo[b][1,6]naphthyridines 5-8 were synthesized by condensation of corresponding anthranilic acids 1,2 with N-alkyl-4-piperidones 3,4 in the presence of phosphorus oxychloride.^{5,6}

Naphthyridine derivate 5 has been reported previously, while 6, 7 and 8 are new compounds. As part of this work it was found that preparation of compounds 5-8 is highly temperature dependent. Thus, heating a mixture of anthranilic acid 1 or 2 (3 mmol), piperidone 3 or 4 (3 mmol), and POCl₃ (20 mL) under reflux for 2 h gave a 2-aminobenzoyl chloride and the desired compounds 5-8 as a major and minor product, respectively. By contrast, the reaction conducted at 60 °C for 5 h under otherwise identical conditions gave 5-8 in high yield after quenching the mixture with aqueous NaHCO₃ (*caution: exothermic reaction*) followed by extraction with ethyl acetate.

An attempted nucleophilic displacement of the chlorine substituent in 5-8 by treatment with an amine alone failed to produce the desired products 9-13, even under forced conditions of temperature and time, and low yield of the product was obtained for the reaction conducted in the presence of phenol. The successful preparation of 9-13 involved heating (120 °C, 10 h, under a nitrogen atmosphere) of 5-8 (1.5 mmol) with an amine (20 mmol) in the presence of a catalytic amount of tin tetrachloride (2 drops). After concentration under reduced pressure, the residue was subjected to silica gel chromatography eluting with AcOEt/MeOH/NEt₃ (17:2:1). The oily products 9-13 were converted to a hydrobromide salt by using a general procedure,⁷ and the salt was crystallized from 95% ethanol.

The methoxy derivative 13 (0.5 mmol) was demethylated by treatment with boron tribromide (0.5 mL, 5.5 mmol) in dichloromethane (10 mL) at 23 °C for 24 h. After quenching with water (0.3 mL) the mixture was treated with ether (20 mL), and the resultant precipitate of a hydrobromide salt of 14 was crystallized from EtOH/MeOH (1:1).

All new products were characterized by ¹H-NMR and ¹³C-NMR and gave satisfactory results of elemental analysis (C, ± 0.3 ; H, ± 0.2 ; N, ± 0.2). The composition, yield, and mp: 6, free base, 91%, 122-123 °C; 7•2HBr•H₂O, 68%, > 200 °C (dec.); 8•2HBr•H₂O, 70%, > 230 °C (dec.); 9•3HBr•1.5H₂O, 42%, 214-215 °C; 10•3HBr•2H₂O, 67%, 221-222 °C; 11•2HBr•3.5H₂O, 39%, 222-224 °C; 12•3HBr•2H₂O, 68%, 203-206 °C (dec.); 13•3HBr•1.5H₂O, 65%, 245-247 °C; 14•3HBr•2H₂O, 56%, 262-265 °C (dec.). Representative ¹³C-NMR spectra (DMSO-*d₆*): 9•3HBr•1.5H₂O, δ 24.8, 41.7, 42.1, 42.6, 47.7, 50.4, 55.4, 104.2, 116.3, 119.2, 124.7, 126.2, 133.6, 137.5, 147.3, 154.3; 10•3HBr•2H₂O, δ 9.2, 24.8, 42.0, 42.8, 45.6, 48.6, 51.2, 55.5, 104.3, 116.2, 119.3, 125.0, 126.5, 134.1, 137.5, 147.2, 154.7; 11•2HBr•3.5H₂O, δ 8.4, 20.2, 21.2, 24.8, 34.0, 42.2, 45.8, 47.6, 50.2, 50.6, 53.7, 104.1, 116.1, 119.2, 124.7, 126.2, 133.7, 137.6, 146.8, 154.5; 13•3HBr•1.5H₂O, δ 9.0, 25.0, 41.8, 42.6, 45.5, 48.5, 50.9, 55.3, 56.7, 105.3, 112.7, 115.7, 117.0, 126.4, 129.0, 147.3, 148.6, 154.4; 14•3HBr•2H₂O, δ 9.1, 25.0, 41.8, 42.8, 45.7, 48.6, 51.1, 55.4, 104.8, 114.3, 115.7, 117.4, 126.7, 128.6, 147.0, 154.5.

References

- 1. R.I. Fox, Semin. Arthritis Rheum. 23, 82 (1993)
- 2. D.J. Wallace, Rheum. Dis. Clin. N. Am. 20, 243 (1994)
- 3. K.R. Schultz and A.L. Gilman, Leuk. Lymphoma 24, 201 (1997)
- 4. L. Strekowski, M. Say, M. Henary, P. Ruiz, L. Manzel, D.E. Macfarlane and A.J. Bojarski, J. Med. Chem. 46, 1242 (2003)
- 5. M. Racanatini, A. Cavalli, F. Belluti, L. Piazzi, A. Rampa, A. Bissi, S. Gobbi, P. Valenti, V. Andrisano, M. Bartolini and V. Cavrini, J. Med. Chem. 43, 2007 (2000)
- 6. M. Papadopoulou, H. Rozuzweig and M. Bloomer, Bioorg. Med. Chem. Lett. 14, 1523 (2004)
- L. Strekowski, J.L. Mokrosz, V.A. Honkan, A. Czarny, M.T. Cegla, R.L. Wydra, S.E. Patterson and R.F. Schinazi, J. Med. Chem. 34, 1739 (1991)

Received on January 18, 2006